A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis

Inclusion Criteria: * You must have active chronic plaque psoriasis for at least 6 months prior to entry into the study * You are a candidate for systemic therapy and/or phototherapy * You must have active plaque psoriasis covering at least 12% body surface area * You must have Psoriasis Area and Severity Index (PASI) score of at least 12 * You must have Static Physician's Global Assessment (sPGA) score of at least 3 Exclusion Criteria: * You must not have received a biologic agent/monoclonal antibody within 8 weeks prior to entry into the study * You must not have prior treatment with an oral Janus kinase (JAK) inhibitor * You must not have received a systemic psoriasis (Ps) therapy within 4 weeks prior to entry into the study * You must not have received a phototherapy within 4 weeks prior to entry into the study * You must not have received a topical Ps therapy with psoralens within 4 weeks prior to entry into the study * You must not be pregnant or nursing * If female of childbearing potential or a male, and do not agree to use 2 forms of highly effective methods of birth control for at least 28 days following the last dose of investigational product * You must not have had symptomatic herpes zoster or herpes simplex infection within 12 weeks or have a history of disseminated/complicated herpes zoster * You must not have evidence of active infection, such as fever ≥38.0ºC (100.4ºF) * You must not have a history of active hepatitis B, hepatitis C, or human immunodeficie…